BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35820129)

  • 1. PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
    Aivalioti MM; Bartholdy BA; Pradhan K; Bhagat TD; Zintiridou A; Jeong JJ; Thiruthuvanathan VJ; Pujato M; Paranjpe A; Zhang C; Levine RL; Viny AD; Wickrema A; Verma A; Will B
    Blood Cancer Discov; 2022 Sep; 3(5):444-467. PubMed ID: 35820129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced PU.1 Expression Collaborates with Tet2 Loss to Trigger Myeloid Leukemogenesis.
    Schleicher WE; Pietras EM
    Blood Cancer Discov; 2022 Sep; 3(5):378-381. PubMed ID: 36065607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.
    Rasmussen KD; Jia G; Johansen JV; Pedersen MT; Rapin N; Bagger FO; Porse BT; Bernard OA; Christensen J; Helin K
    Genes Dev; 2015 May; 29(9):910-22. PubMed ID: 25886910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis.
    Tulstrup M; Soerensen M; Hansen JW; Gillberg L; Needhamsen M; Kaastrup K; Helin K; Christensen K; Weischenfeldt J; Grønbæk K
    Nat Commun; 2021 Oct; 12(1):6061. PubMed ID: 34663818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation.
    Xie J; Sheng M; Rong S; Zhou D; Wang C; Wu W; Huang J; Sun Y; Wang Y; Chen P; Wu Y; Wang Y; Wang L; Zhou BO; Huang X; Walsh CP; Bohlander SK; Huang J; Wang X; Xu GL; Gao H; Shi Y
    Leukemia; 2023 Dec; 37(12):2457-2467. PubMed ID: 37816954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.
    Burda P; Vargova J; Curik N; Salek C; Papadopoulos GL; Strouboulis J; Stopka T
    PLoS One; 2016; 11(3):e0152234. PubMed ID: 27010793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
    Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
    Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
    Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
    Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
    Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
    Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
    Steidl U; Rosenbauer F; Verhaak RG; Gu X; Ebralidze A; Otu HH; Klippel S; Steidl C; Bruns I; Costa DB; Wagner K; Aivado M; Kobbe G; Valk PJ; Passegué E; Libermann TA; Delwel R; Tenen DG
    Nat Genet; 2006 Nov; 38(11):1269-77. PubMed ID: 17041602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia.
    Will B; Vogler TO; Narayanagari S; Bartholdy B; Todorova TI; da Silva Ferreira M; Chen J; Yu Y; Mayer J; Barreyro L; Carvajal L; Neriah DB; Roth M; van Oers J; Schaetzlein S; McMahon C; Edelmann W; Verma A; Steidl U
    Nat Med; 2015 Oct; 21(10):1172-81. PubMed ID: 26343801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 mutation as prototypic clonal hematopoiesis lesion.
    Guarnera L; Jha BK
    Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells.
    Mattes K; Geugien M; Korthuis PM; Brouwers-Vos AZ; Fehrmann RSN; Todorova TI; Steidl U; Vellenga E; Schepers H
    Exp Hematol; 2019 May; 73():38-49.e7. PubMed ID: 30986495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
    Nakajima H; Kunimoto H
    Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2: A cornerstone in normal and malignant hematopoiesis.
    Kunimoto H; Nakajima H
    Cancer Sci; 2021 Jan; 112(1):31-40. PubMed ID: 33048426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
    Chan SM; Majeti R
    Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
    Rasmussen KD; Berest I; Keβler S; Nishimura K; Simón-Carrasco L; Vassiliou GS; Pedersen MT; Christensen J; Zaugg JB; Helin K
    Genome Res; 2019 Apr; 29(4):564-575. PubMed ID: 30796038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.